A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy | Zendy

K.-C. Chang | Zendy; ChienHui Hung | Zendy; S.-N. Lu | Zendy; J.-H. Wang | Zendy; C.-M. Lee | Zendy; ChiaHsiang Chen | Zendy; Miaofen Yen | Zendy; ShihChieh Lin | Zendy; YiHao Yen | Zendy; MingChang Tsai | Zendy; PoLin Tseng | Zendy; TsungHui Hu | Zendy

Open Access

A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy

Author(s) -

K.-C. Chang,

ChienHui Hung,

S.-N. Lu,

J.-H. Wang,

C.-M. Lee,

ChiaHsiang Chen,

Miaofen Yen,

ShihChieh Lin,

YiHao Yen,

MingChang Tsai,

PoLin Tseng,

TsungHui Hu

Publication year - 2012

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dks269

Subject(s) - medicine , ribavirin , hepatocellular carcinoma , pegylated interferon , gastroenterology , hazard ratio , proportional hazards model , risk factor , confidence interval , chronic hepatitis , immunology , virus

Antiviral therapy can prevent the development of hepatocellular carcinoma (HCC) in chronic hepatitis C (CHC) patients. However, HCC still develops in patients achieving sustained virological response (SVR). We proposed to evaluate the risk factors and derive a novel risk score for HCC (score(HCC)) by summation of products of clinical weights based on the regression coefficients in the final proportional hazards model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research